
Viatris and Idorsia have announced that they have entered into agreements for a significant global research and development collaboration. Under …

Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and it is potentially worth more …

As part of Johnson & Johnson’s acquisition of Actelion, it was able to secure a number of ties with the …

Idorsia, the spin-off R&D company of Actelion, has been hit a blow even before it has left the ground. The …

